Stocks To Watch- Zomato, Tata Power, BHEL, Rail Vikas Nigam, Ajanta Pharma, Spandana Sphoorty Financial

Stocks To Watch: Zomato, Tata Power, BHEL, Rail Vikas Nigam, Ajanta Pharma, Spandana Sphoorty Financial

Stocks in focus: GIFT Nifty traded 0.01% higher during Thursday’s early trading session at 19,480.5, indicating a flat opening for domestic indices NSE Nifty 50 and BSE Sensex. The equity benchmarks closed flat on Wednesday, paring most intraday gains. Nifty 50 settled higher by 0.02% at 19,347.45 while Sensex gained 65,087.25, higher by 11 points.

“Positive sentiment initially propelled domestic equities, buoyed by softer US labour market data that caused a retreat in US bond yields, alleviating concerns about rate hikes. This positive outlook was reinforced by Chinese banks’ move to reduce existing mortgage rates, favourably impacting Indian metal stocks. However, gains were tempered as the day progressed, primarily due to weakness in global markets attributed to lacklustre economic data from Europe. Banking stocks bore the brunt of this downturn, while mid- and small-cap segments displayed resilience amid the market dynamics,” said Vinod Nair, Head of Research at Geojit Financial Services.

Tata Power

Tata Power Delhi Distribution (Tata Power-DDL) has received a three-year extension till 2026 from the Department of Scientific and Industrial Research (DSIR) for its in-house R&D unit. Tata Power Delhi Distribution is a joint venture between Tata Power and the government of NCT of Delhi.

BHEL

Bharat Heavy Electricals company has won an order for setting up 2×800 MW Supercritical Thermal Power Project Stage-II at Lara in Chhattisgarh through international competitive bidding. The scope of work included designing, engineering, manufacture, supply, construction, erection, testing and commissioning projects with civil and structural works for the EPC project.

RVNL

Rail Vikas Nigam emerged as the lowest bidder (L1) for a series of projects under the Maharashtra Metro Rail Corporation (Maha Metro) purview. The total consideration for the project is around Rs 256.19 crore.

Ajanta Pharma

Ajanta Pharma secured final clearance from the United States Food and Drug Administration to market topiramate extended-release capsules in dosages of 25 mg, 50 mg, 100 mg, and 200 mg. This endorsement stems from an agreement with the original developer, positioning Ajanta Pharma for a potential launch of topiramate by or before February 1, 2026.

Spandana Sphoorty Financial

On Wednesday, a total of four entities chose to sell shares of Spandana Sphoorty Financial for an approximate amount of Rs 268 crore, utilizing open market transactions for the sale. These entities include Valiant Mauritius Partners FDI, Valiant India Opportunities, Valiant Mauritius Partners, and Valiant Mauritius Partners Offshore.

(With agency inputs.)